Hippo信号通路与心血管发育及疾病调控

doi:10.16288/j.yczz.17-039

遗传 ›› 2017, Vol. 39 ›› Issue (7): 576-587.doi: 10.16288/j.yczz.17-039

Hippo信号通路与心血管发育及疾病调控

王永煜¹(),余薇²,周斌²()

1. 温州医科大学基础医学院,温州 325035
2. 中国科学院上海生命科学研究院生物化学与细胞生物学研究所,细胞生物学国家重点实验室,上海 200031

收稿日期:2017-02-09 修回日期:2017-03-07 出版日期:2017-07-20 发布日期:2017-05-23
作者简介:王永煜，博士，研究员，研究方向：干细胞与心血管再生。E-mail：yywangut@163.com|周斌，博士，研究员，研究方向：心血管发育与再生。E-mail：zhoubin@sibs.ac.cn
基金资助:
国家自然科学基金项目(编号：81670454,81270321,31625019,91639302)资助[Supported by the National Natural Science Foundation of China (Nos. 81670454, 81270321, 31625019, 91639302)]

Hippo signaling pathway in cardiovascular development and diseases

Wang Yongyu¹(),Yu Wei²,Zhou Bin²()

1. College of Basic Medical Sciences, Wenzhou Medical University, Wenzhou 325035, China
2. State Key Laboratory of Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China

Received:2017-02-09 Revised:2017-03-07 Online:2017-07-20 Published:2017-05-23

摘要/Abstract

摘要：

心血管疾病已成为中国乃至全球首位死亡原因,探索心血管系统发育及调控异常的原因及相关机制可以为心血管疾病的预防和治疗提供重要的科学依据。Hippo信号通路是新近发现的在调节器官大小、细胞增殖及凋亡、干细胞命运等方面具有重要功能的一条信号通路。Hippo信号通路的不同成分参与心脏血管的发育和心血管细胞增殖、分化等功能调控,影响损伤后修复及再生等过程,该通路调节异常可引起心血管疾病,如心梗、心肌肥大、血管内膜增生、动脉硬化等。本文综述了Hippo信号通路对心血管系统发育和疾病调控的相关研究及最新进展,以期为Hippo通路在心血管疾病的发病机制及临床转化研究提供潜在的理论基础。

关键词: Hippo/YAP, 心脏发育, 心肌再生, 心血管疾病, 动脉硬化

Abstract:

Cardiovascular diseases have become the leading cause of death in the world. Understanding the development of cardiovascular system and the pathogenesis of cardiovascular diseases will promote the generation of novel preventive and therapeutic strategy. The Hippo pathway is a recently identified signaling cascade that plays a critical role in organ size control, cell proliferation, apoptosis and fate determination of stem cells. Gene knockout and transgenic mouse models have revealed that the Hippo signaling pathway is involved in heart development, cardiomyocyte proliferation, apoptosis, hypertrophy and cardiac regeneration. The Hippo signaling pathway also regulates vascular development, differentiation and various functions of vascular cells. Dysregulation of the Hippo signaling pathway leads to different kinds of cardiovascular diseases, such as myocardial infarction, cardiac hypertrophy, neointima formation and atherosclerosis. In this review, we briefly summarize current research on the roles and regulation mechanisms of the Hippo signaling pathway in cardiovascular development and diseases.

Key words: Hippo/YAP, heart development, cardiac regeneration, cardiovascular diseases, atherosclerosis

王永煜,余薇,周斌. Hippo信号通路与心血管发育及疾病调控[J]. 遗传, 2017, 39(7): 576-587.

Wang Yongyu,Yu Wei,Zhou Bin. Hippo signaling pathway in cardiovascular development and diseases[J]. Hereditas(Beijing), 2017, 39(7): 576-587.

参考文献

[1]	Zhou Q, Li L, Zhao B, Guan KL. The hippo pathway in heart development, regeneration, and diseases. Circ Res, 2015, 116(8): 1431-1447.
[2]	Yu FX, Zhao B, Guan KL. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell, 2015, 163(4): 811-828.
[3]	McPherson JP, Tamblyn L, Elia A, Migon E, Shehabeldin A, Matysiak-Zablocki E, Lemmers B, Salmena L, Hakem A, Fish J, Kassam F, Squire J, Bruneau BG, Hande MP, Hakem R. Lats2/Kpm is required for embryonic development, proliferation control and genomic integrity. EMBO J, 2004, 23(18): 3677-3688.
[4]	Heallen T, Zhang M, Wang J, Bonilla-Claudio M, Klysik E, Johnson RL, Martin JF. Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science, 2011, 332(6028): 458-461.
[5]	Song H, Mak KK, Topol L, Yun KS, Hu J, Garrett L, Chen YB, Park O, Chang J, Simpson RM, Wang CY, Gao B, Jiang J, Yang YZ. Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci USA, 2010, 107(4): 1431-1436.
[6]	Matsui Y, Nakano N, Shao D, Gao SM, Luo WT, Hong C, Zhai PY, Holle E, Yu XZ, Yabuta N, Tao WF, Wagner T, Nojima H, Sadoshima J. Lats2 is a negative regulator of myocyte size in the heart. Circ Res, 2008, 103(11): 1309-1318.
[7]	Morin-Kensicki EM, Boone BN, Howell M, Stonebraker JR, Teed J, Alb JG, Magnuson TR, O'Neal W, Milgram SL. Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of Yap65. Mol Cell Biol, 2006, 26(1): 77-87.
[8]	Xin M, Kim Y, Sutherland LB, Murakami M, Qi XX, McAnally J, Porrello ER, Mahmoud AI, Tan W, Shelton JM, Richardson JA, Sadek HA, Bassel-Duby R, Olson EN. Hippo pathway effector Yap promotes cardiac regeneration. Proc Natl Acad Sci USA, 2013, 110(34): 13839-13844.
[9]	Xin M, Kim Y, Sutherland LB, Qi XX, McAnally J, Schwartz RJ, Richardson JA, Bassel-Duby R, Olson EN. Regulation of insulin-like growth factor signaling by Yap governs cardiomyocyte proliferation and embryonic heart size. Sci Signal, 2011, 4(196): ra70
[10]	von Gise A, Lin ZQ, Schlegelmilch K, Honor LB, Pan GM, Buck JN, Ma Q, Ishiwata T, Zhou B, Camargo FD, Pu WT. YAP1, the nuclear target of Hippo signaling, stimulates heart growth through cardiomyocyte proliferation but not hypertrophy. Proc Natl Acad Sci USA, 2012, 109(7): 2394-2399.
[11]	Miesfeld JB, Link BA. Establishment of transgenic lines to monitor and manipulate Yap/Taz-Tead activity in zebrafish reveals both evolutionarily conserved and divergent functions of the Hippo pathway. Mech Dev, 2014, 133: 177-188.
[12]	Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH, Zhao JG, Yuan HX, Tumaneng K, Li HR, Fu XD, Mills GB, Guan KL. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell, 2012, 150(4): 780-791.
[13]	Zhao B, Ye X, Yu JD, Li L, Li WQ, Li SM, Yu JJ, Lin JD, Wang CY, Chinnaiyan AM, Lai ZC, Guan KL. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev, 2008, 22(14): 1962-1971.
[14]	Wu SA, Liu Y, Zheng YG, Dong JX, Pan DJ. The TEAD/TEF family protein Scalloped mediates transcriptional output of the Hippo growth-regulatory pathway. Dev Cell, 2008, 14(3): 388-398.
[15]	Chen Z, Friedrich GA, Soriano P. Transcriptional enhancer factor 1 disruption by a retroviral gene trap leads to heart defects and embryonic lethality in mice. Genes Dev, 1994, 8(19): 2293-2301.
[16]	Tsika RW, Ma LX, Kehat I, Schramm C, Simmer G, Morgan B, Fine DM, Hanft LM, McDonald KS, Molkentin JD, Krenz M, Yang S, Ji J. TEAD-1 overexpression in the mouse heart promotes an age-dependent heart dysfunction. J Biol Chem, 2010, 285(18): 13721-13735.
[17]	Kwon C, Arnold J, Hsiao EC, Taketo MM, Conklin BR, Srivastava D. Canonical Wnt signaling is a positive regulator of mammalian cardiac progenitors. Proc Natl Acad Sci USA, 2007, 104(26): 10894-10899.
[18]	Graves JD, Gotoh Y, Draves KE, Ambrose D, Han DKM, Wright M, Chernoff J, Clark EA, Krebs EG. Caspase-mediated activation and induction of apoptosis by the mammalian Ste20-like kinase Mst1. EMBO J, 1998, 17(8): 2224-2234.
[19]	Yamamoto S, Yang GP, Zablocki D, Liu J, Hong C, Kim SJ, Soler S, Odashima M, Thaisz J, Yehia G, Molina CA, Yatani A, Vatner DE, Vatner SF, Sadoshima J. Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy. J Clin Invest, 2003, 111(10): 1463-1474.
[20]	Odashima M, Usui S, Takagi H, Hong C, Liu J, Yokota M, Sadoshima J. Inhibition of endogenous Mst1 prevents apoptosis and cardiac dysfunction without affecting cardiac hypertrophy after myocardial infarction. Circ Res, 2007, 100(9): 1344-1352.
[21]	Del Re DP, Matsuda T, Zhai PY, Gao SM, Clark GJ, Van Der Weyden L, Sadoshima J. Proapoptotic Rassf1A/Mst1 signaling in cardiac fibroblasts is protective against pressure overload in mice. J Clin Invest, 2010, 120(10): 3555-3567.
[22]	Del Re DP, Matsuda T, Zhai PY, Maejima Y, Jain MR, Liu T, Li H, Hsu CP, Sadoshima J. Mst1 promotes cardiac myocyte apoptosis through phosphorylation and inhibition of Bcl-xL. Mol Cell, 2014, 54(4): 639-650.
[23]	Oceandy D, Pickard A, Prehar S, Zi M, Mohamed TMA, Stanley PJ, Baudoin-Stanley F, Nadif R, Tommasi S, Pfeifer GP, Armesilla AL, Cartwright EJ, Neyses L. Tumor suppressor Ras-association domain family 1 isoform A is a novel regulator of cardiac hypertrophy. Circulation, 2009, 120(7): 607-616.
[24]	Maejima Y, Kyoi S, Zhai PY, Liu T, Li H, Ivessa A, Sciarretta S, Del Re DP, Zablocki DK, Hsu CP, Lim DS, Isobe M, Sadoshima J. Mst1 inhibits autophagy by promoting the interaction between Beclin1 and Bcl-2. Nat Med, 2013, 19(11): 1478-1488.
[25]	Nakamura M, Zhai PY, Del Re DP, Maejima Y, Sadoshima J. Mst1-mediated phosphorylation of Bcl-xL is required for myocardial reperfusion injury. JCI Insight, 2016, 1(5): e86217.
[26]	Del Re DP, Yang YF, Nakano N, Cho J, Zhai PY, Yamamoto T, Zhang NL, Yabuta N, Nojima H, Pan DJ, Sadoshima J. Yes-associated protein isoform 1 (Yap1) promotes cardiomyocyte survival and growth to protect against myocardial ischemic injury. J Biol Chem, 2013, 288(6): 3977-3988.
[27]	Matsuda T, Zhai PY, Sciarretta S, Zhang Y, Jeong JI, Ikeda S, Park J, Hsu CP, Tian B, Pan DJ, Sadoshima J, Del Re DP. NF2 Activates Hippo signaling and promotes ischemia/reperfusion injury in the heart. Circ Res, 2016, 119(5): 596-606.
[28]	Porrello ER, Mahmoud AI, Simpson E, Hill JA, Richardson JA, Olson EN, Sadek HA. Transient regenerative potential of the neonatal mouse heart. Science, 2011, 331(6020): 1078-1080.
[29]	Zhou DW, Zhang YY, Wu HT, Barry E, Yin Y, Lawrence E, Dawson D, Willis JE, Markowitz SD, Camargo FD, Avruch J. Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proc Natl Acad Sci USA, 2011, 108(49): E1312-E1320.
[30]	Schlegelmilch K, Mohseni M, Kirak O, Pruszak J, Rodriguez JR, Zhou DW, Kreger BT, Vasioukhin V, Avruch J, Brummelkamp TR, Camargo FD. Yap1 acts downstream of α-catenin to control epidermal proliferation. Cell, 2011, 144(5): 782-795.
[31]	Zhou DW, Conrad C, Xia F, Park JS, Payer B, Yin Y, Lauwers GY, Thasler W, Lee JT, Avruch J, Bardeesy N. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell, 2009, 16(5): 425-438.
[32]	Heallen T, Morikawa Y, Leach J, Tao G, Willerson JT, Johnson RL, Martin JF. Hippo signaling impedes adult heart regeneration. Development, 2013, 140(23): 4683-4690.
[33]	Lin ZQ, von Gise A, Zhou PZ, Gu F, Ma Q, Jiang JM, Yau AL, Buck JN, Gouin KA, van Gorp PR, Zhou B, Chen JH, Seidman JG, Wang DZ, Pu WT. Cardiac-specific YAP activation improves cardiac function and survival in an experimental murine MI model. Circ Res, 2014, 115(3): 354-363.
[34]	Lin ZQ, Zhou PZ, von Gise A, Gu F, Ma Q, Chen JH, Guo HD, van Gorp PRR, Wang DZ, Pu WT. Pi3kcb links Hippo-YAP and PI3K-AKT signaling pathways to promote cardiomyocyte proliferation and survival. Circ Res, 2015, 116(1): 35-45.
[35]	Duboc V, Rottinger E, Lapraz F, Besnardeau L, Lepage T. Left-right asymmetry in the sea urchin embryo is regulated by nodal signaling on the right side. Dev Cell, 2005, 9(1): 147-158.
[36]	Tao G, Kahr PC, Morikawa Y, Zhang M, Rahmani M, Heallen TR, Li LL, Sun Z, Olson EN, Amendt BA, Martin JF. Pitx2 promotes heart repair by activating the antioxidant response after cardiac injury. Nature, 2016, 534(7605): 119-123.
[37]	Eulalio A, Mano M, Dal Ferro M, Zentilin L, Sinagra G, Zacchigna S, Giacca M. Functional screening identifies miRNAs inducing cardiac regeneration. Nature, 2012, 492(7429): 376-381.
[38]	Tian Y, Liu Y, Wang T, Zhou N, Kong J, Chen L, Snitow M, Morley M, Li DQ, Petrenko N, Zhou S, Lu MM, Gao EH, Koch WJ, Stewart KM, Morrisey EE. A microRNA-Hippo pathway that promotes cardiomyocyte proliferation and cardiac regeneration in mice. Sci Transl Med, 2015, 7(279): 279ra238.
[39]	Yang YF, Del Re DP, Nakano N, Sciarretta S, Zhai PY, Park J, Sayed D, Shirakabe A, Matsushima S, Park Y, Tian B, Abdellatif M, Sadoshima J. MiR-206 mediates YAP-induced cardiac hypertrophy and survival. Circ Res, 2015, 117(10): 891-904.
[40]	Morisco C, Sadoshima J, Trimarco B, Arora R, Vatner DE, Vatner SF. Is treating cardiac hypertrophy salutary or detrimental: the two faces of Janus. Am J Physiol Heart Circ Physiol, 2003, 284(4): H1043-E1047.
[41]	Zi M, Maqsood A, Prehar S, Mohamed TMA, Abou-Leisa R, Robertson A, Cartwright EJ, Ray SG, Oh S, Lim DS, Neyses L, Oceandy D. The mammalian Ste20-like kinase 2 (Mst2) modulates stress-induced cardiac hypertrophy. J Biol Chem, 2014, 289(35): 24275-24288.
[42]	Fan FQ, He ZX, Kong LL, Chen QH, Yuan Q, Zhang SH, Ye JJ, Liu H, Sun XF, Geng J, Yuan LZ, Hong LX, Xiao C, Zhang WJ, Sun XH, Li YZ, Wang P, Huang LH, Wu XR, Ji ZL, Wu Q, Xia NS, Gray NS, Chen LF, Yun CH, Deng XM, Zhou DW. Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration. Sci Transl Med, 2016, 8(352): 352ra108.
[43]	Shao D, Zhai PY, Del Re DP, Sciarretta S, Yabuta N, Nojima H, Lim DS, Pan DJ, Sadoshima J. A functional interaction between Hippo-YAP signalling and FoxO1 mediates the oxidative stress response. Nat Commun, 2014, 5: 3315.
[44]	Hamaratoglu F, Willecke M, Kango-Singh M, Nolo R, Hyun E, Tao C, Jafar-Nejad H, Halder G. The tumour- suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol, 2006, 8(1): 27-36.
[45]	Zhang NL, Bai HB, David KK, Dong JX, Zheng YG, Cai J, Giovannini M, Liu PT, Anders RA, Pan DJ. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell, 2010, 19(1): 27-38.
[46]	Yin F, Yu JZ, Zheng YG, Chen Q, Zhang NL, Pan DJ. Spatial organization of hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell, 2013, 154(6): 1342-1355.
[47]	Basso C, Corrado D, Marcus FI, Nava A, Thiene G. Arrhythmogenic right ventricular cardiomyopathy. Lancet, 2009, 373(9671): 1289-1300.
[48]	Chen SN, Gurha P, Lombardi R, Ruggiero A, Willerson JT, Marian AJ. The Hippo pathway is activated and is a causal mechanism for adipogenesis in arrhythmogenic cardiomyopathy. Circ Res, 2014, 114(3): 454-468.
[49]	Varelas X, Miller BW, Sopko R, Song SY, Gregorieff A, Fellouse FA, Sakuma R, Pawson T, Hunziker W, McNeill H, Wrana JL, Attisano L. The Hippo pathway regulates Wnt/β-catenin signaling. Dev Cell, 2010, 18(4): 579-591.
[50]	Zhang H, von Gise A, Liu QZ, Hu TY, Tian XY, He LJ, Pu WJ, Huang XZ, He L, Cai CL, Camargo FD, Pu WT, Zhou B. Yap1 is required for endothelial to mesenchymal transition of the atrioventricular cushion. J Biol Chem, 2014, 289(27): 18681-18692.
[51]	Wang Y, Hu GQ, Liu F, Wang XB, Wu MF, Schwarz JJ, Zhou JL. Deletion of yes-associated protein (YAP) specifically in cardiac and vascular smooth muscle cells reveals a crucial role for YAP in mouse cardiovascular development. Circ Res, 2014, 114(6): 957-965.
[52]	Wang LC, Qiu P, Jiao J, Hirai H, Xiong W, Zhang JF, Zhu TQ, Ma PX, Chen YE, Yang B. Yes-associated protein inhibits transcription of myocardin and attenuates differentiation of vascular smooth muscle cell from cardiovascular progenitor cell lineage. Stem Cells, 2017, 35(2): 351-361.
[53]	Manderfield LJ, Aghajanian H, Engleka KA, Lim LY, Liu FY, Jain R, Li L, Olson EN, Epstein JA. Hippo signaling is required for Notch-dependent smooth muscle differentiation of neural crest. Development, 2015, 142(17): 2962-2971.
[54]	Singh A, Ramesh S, Cibi DM, Yun LS, Li J, Li L, Manderfield LJ, Olson EN, Epstein JA, Singh MK. Hippo signaling mediators Yap and Taz are required in the epicardium for coronary vasculature development. Cell Rep, 2016, 15(7): 1384-1393.
[55]	Choi HJ, Zhang HY, Park H, Choi KS, Lee HW, Agrawal V, Kim YM, Kwon YG. Yes-associated protein regulates endothelial cell contact-mediated expression of angiopoietin-2. Nat Commun, 2015, 6: 6943.
[56]	Dai XM, She PL, Chi FT, Feng Y, Liu H, Jin DQ, Zhao YQ, Guo XC, Jiang DD, Guan KL, Zhong TP, Zhao B. Phosphorylation of angiomotin by Lats1/2 kinases inhibits F-actin binding, cell migration, and angiogenesis. J Biol Chem, 2013, 288(47): 34041-34051.
[57]	Kimura TE, Duggirala A, Smith MC, White S, Sala- Newby GB, Newby AC, Bond M. The Hippo pathway mediates inhibition of vascular smooth muscle cell proliferation by cAMP. J Mol Cell Cardiol, 2016, 90: 1-10.
[58]	Wang XB, Hu GQ, Gao XW, Wang Y, Zhang W, Harmon EY, Zhi X, Xu ZP, Lennartz MR, Barroso M, Trebak M, Chen CS, Zhou JL. The induction of yes-associated protein expression after arterial injury is crucial for smooth muscle phenotypic modulation and neointima formation. Arterioscler Thromb Vasc Biol, 2012, 32(11): 2662-2669.
[59]	Xie CQ, Guo YH, Zhu TQ, Zhang JF, Ma PX, Chen YE. Yap1 protein regulates vascular smooth muscle cell phenotypic switch by interaction with myocardin. J Biol Chem, 2012, 287(18): 14598-14605.
[60]	Shen ZW, Stanger BZ. YAP regulates S-phase entry in endothelial cells. PLoS One, 2015, 10(1): e0117522.
[61]	Giampietro C, Disanza A, Bravi L, Barrios-Rodiles M, Corada M, Frittoli E, Savorani C, Lampugnani MG, Boggetti B, Niessen C, Wrana JL, Scita G, Dejana E. The actin-binding protein EPS8 binds VE-cadherin and modulates YAP localization and signaling. J Cell Biol, 2015, 211(6): 1177-1192.
[62]	Xu SW, Koroleva M, Yin MM, Jin ZG. Atheroprotective laminar flow inhibits Hippo pathway effector YAP in endothelial cells. Transl Res, 2016, 176: 18-28.e12.
[63]	Feng X, Liu P, Zhou X, Li MT, Li FL, Wang Z, Meng Z, Sun YP, Yu Y, Xiong Y, Yuan HX, Guan KL. Thromboxane A2 activates YAP/TAZ protein to induce vascular smooth muscle cell proliferation and migration. J Biol Chem, 2016, 291(36): 18947-18958.
[64]	Wang L, Luo JY, Li BC, Tian XY, Chen LJ, Huang YH, Liu J, Deng D, Lau CW, Wan S, Ai D, Mak KLK, Tong KK, Kwan KM, Wang NP, Chiu JJ, Zhu Y, Huang Y. Integrin-YAP/TAZ-JNK cascade mediates atheroprotective effect of unidirectional shear flow. Nature, 2016, 540(7634): 579-582.
[65]	Kudryashova TV, Goncharov DA, Pena A, Kelly N, Vanderpool R, Baust J, Kobir A, Shufesky W, Mora AL, Morelli AE, Zhao J, Ihida-Stansbury K, Chang BJ, DeLisser H, Tuder RM, Kawut SM, Silljé HHW, Shapiro S, Zhao YT, Goncharova EA. Hippo-integrin-linked kinase cross- talk controls self-sustaining proliferation and survival in pulmonary hypertension. Am J Respir Crit Care Med, 2016, 194(7): 866-877.
[66]	Li HY, Jiang WJ, Ren WH, Guo D, Guo JL, Wang XL, Liu YY, Lan F, Du J, Zhang HJ. Downregulation of the Yes-associated protein is associated with extracellular matrix disorders in ascending aortic aneurysms. Stem Cells Int, 2016, 2016: 6786184.

编辑推荐

Metrics

www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:

Hippo信号通路与心血管发育及疾病调控

Hippo signaling pathway in cardiovascular development and diseases

RichHTML

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 8

编辑推荐

Metrics

[1]	孙兆庆, 闫波. 转录因子GATA6在心血管疾病中的作用及其调控机制[J]. 遗传, 2019, 41(5): 375-383.
[2]	李玉席, 李俊宏, 周大旺. Hippo信号通路与肝脏稳态调控及疾病发生[J]. 遗传, 2017, 39(7): 607-616.
[3]	曹丽娟,刘昕訸,查晴,宋倩,杨克,刘艳. SIRT3与细胞代谢及心血管疾病的相关性[J]. 遗传, 2015, 37(2): 111-120.
[4]	许飞, 张进, 马端. Hippo/YAP和Wnt/β-catenin通路的对话[J]. 遗传, 2014, 36(2): 95-102.
[5]	甄一松，惠汝太，熊敬维. 心脏的再生性研究进展[J]. 遗传, 2011, 33(11): 1159-1163.
[6]	王跃群，刘明耀，吴秀山. 心肌细胞形成和分化过程中钙信号转导调控得研究进展[J]. 遗传, 2004, 26(2): 227-230.
[7]	汪宪平，颜中，其梅，蔡险峰，张海国，沈若崖，陈仁彪. 人类单纯性先天性心脏病中TBX5基因的突变及表达研究[J]. 遗传, 2003, 4(5): 533-537.
[8]	杨粤军，吴秀山，李敏，. 果蝇心脏发育起调控作用的候选基因的筛选 [J]. 遗传, 2002, 24(6): 667-669.